http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2089708-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9272cd1eb8879dbfab8bf24afa55a73e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6284dff86ce81628fea97a215cab18b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2007-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa3cf8d7aa122f151e56055d78cde22c |
| publicationDate | 2012-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2089708-B1 |
| titleOfInvention | Cancer immunotherapy predictive parameters |
| abstract | The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: - providing a blood sample of said individual, - (a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and - (bl) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number Of lymphocytes is below or equal to a lymphocyte baseline level of 1,4 to 1,8 x 109 per liter blood, especially below or equal to 1,6 x 109 per liter blood; or (b2) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number of neutrophils is below or equal to a neutrophil baseline level of from 4,0 to 6,0 x 109 per liter blood, especially below or equal to 5,0 x 109 neutrophils per liter blood; or (b3) identifying the individual as not having a predictive clinical benefit, if the number of lymphocytes is above a lymphocyte baseline level of 1,4 to 1,8 x 109 per liter blood, especially above 1,6 x 109 per liter blood and the number of neutrophils is above a neutrophil baseline level of from 4,0 to 6,0 x 109 per liter blood, especially above 5,0 x 109 neutrophils per liter blood. |
| priorityDate | 2006-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.